

LEXICON PHARMACEUTICALS, INC./DE

Form 8-K

September 25, 2007

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 19, 2007

Lexicon Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

000-30111
(Commission File Number)

76-0474169
(I.R.S. Employer
Identification Number)

8800 Technology Forest Place
The Woodlands, Texas 77381
(Address of principal executive
offices and Zip Code)

(281) 863-3000
(Registrant's telephone number,
including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b) On September 19, 2007, Clayton S. Rose, Ph.D. and, on September 21, 2007, Barry Mills, J.D., Ph.D. notified us of their decisions to resign from our board of directors, in each case effective September 30, 2007.

(d) Effective September 24, 2007, our board of directors elected Judith L. Swain, M.D. to serve as a member of our board of directors.

The election of Dr. Swain as a director was not made pursuant to any arrangement or understanding between Dr. Swain and any other person. Dr. Swain will not initially serve on any committees of the board of directors, and we have no current expectation as to which committees, if any, Dr. Swain may ultimately be appointed. There are no current or proposed transactions in which Dr. Swain or any member of her immediate family has, or will have, a direct or indirect material interest which would require disclosure under Item 404(a) of Regulation S-K.

Dr. Swain will receive compensation for her service as a director consistent with our standard arrangements for non-employee directors as follows:

an annual retainer of \$15,000, prorated for partial years of service;

a fee of \$2,500 for each meeting of the board of directors that she attends in person (\$500 for each telephonic meeting of the board of directors in which she participates);

reimbursement for expenses in connection with attendance at meetings of the board of directors;

an initial option under our 2000 Non-Employee Directors Stock Option Plan to purchase 30,000 shares of common stock at an exercise price of \$3.31 per share, the fair market value of our common stock on the date of grant as determined in accordance with the plan; and

commencing on the day following our 2008 annual meeting of stockholders, an annual option under the plan to purchase 10,000 shares of common stock at an exercise price equal to the fair market value of our common stock on the date of grant as determined in accordance with the plan.

Consistent with our standard arrangements for non-employee directors, Dr. Swain will receive additional cash compensation if she is appointed to any committee of the board of directors. We have also entered into an indemnification agreement with Dr. Swain in the standard form previously entered into with our other officers and directors.

A copy of our press release announcing Dr. Swain's election to our board of directors is attached to this current report on Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Press Release of Lexicon Pharmaceuticals, Inc. dated September 25, 2007

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Lexicon Pharmaceuticals, Inc.

Date: September 25, 2007

By: /s/ Jeffrey L. Wade
Jeffrey L. Wade
*Executive Vice President and
General Counsel*

Index to Exhibits

Exhibit No.

Description

99.1

Press Release of Lexicon Pharmaceuticals, Inc. dated September 25, 2007

5